News coverage about ObsEva (NASDAQ:OBSV) has been trending positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ObsEva earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.8601160058281 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- ObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call Transcript (fool.com)
- ObsEva SA: ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update (finanznachrichten.de)
- ObsEva’ (OBSV) CEO Ernest Loumaye Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)
- ObsEva (OBSV) Posts Earnings Results, Misses Expectations By $0.08 EPS (americanbankingnews.com)
- ObsEva SA NASDAQ:OBSV is reporting this earnings, what to expect. (stockmarketdaily.co)
Shares of ObsEva stock opened at $13.40 on Friday. The stock has a market cap of $453.73 million, a PE ratio of -5.96 and a beta of 2.82. ObsEva has a twelve month low of $5.00 and a twelve month high of $15.81.
A number of equities research analysts have commented on OBSV shares. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of ObsEva in a report on Monday, February 5th. Leerink Swann raised their price objective on ObsEva from $17.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Credit Suisse Group restated a “buy” rating and set a $18.00 price objective (up previously from $16.00) on shares of ObsEva in a research report on Tuesday, February 27th. BMO Capital Markets restated a “buy” rating and set a $24.00 price objective on shares of ObsEva in a research report on Tuesday, February 27th. Finally, Zacks Investment Research lowered ObsEva from a “hold” rating to a “sell” rating in a research report on Tuesday, March 6th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $20.00.
ObsEva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.